Effects of 6-Month Sitagliptin Treatment on Glucose and Lipid Metabolism, Blood Pressure, Body Weight and Renal Function in Type 2 Diabetic Patients: A Chart-Based Analysis

Abstract

BackgroundSitagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the inactivation of incretins, increasing the endogenous active incretin levels. Incretins stimulate insulin secretion from pancreatic β-cells and inhibit glucagon secretion from pancreatic α-cells, which is favorable for the treatment of diabetes. Sitagliptin is released on December, 2009, in Japan. We retrospectively studied effects of 6-month-treatment with sitagliptin on glucose and lipid metabolism, blood pressure, body weight and renal function in patients with type 2 diabetes by a chart-based analysis.MethodsWe retrospectively studied 220 type 2 diabetic patients who have taken sitagliptin for 6 months by a chart-based analysis. Subjects studied include patients treated with sitagliptin monotherapy, sitagliptin add-on therapy, and switching from glinide to sitagliptin. We selected patients who have both data before and after 6-month sitagliptin treatment and compared the data before the sitagliptin treatment with the data at 6 month after the sitagliptin treatment started. Body weight, blood pressure, plasma glucose, hemoglobin A1c (HbA1c), serum lipids, and estimated glomerular filtration rate in type 2 diabetic patients were measured almost at the same time points before and after 6-month-treatment with sitagliptin.ResultsBody weight was significantly reduced after 6-month sitagliptin treatment by 0.8 kg. HbA1c levels were also significantly decreased after the sitagliptin treatment by 0.6%. We found a significant and negative correlation between change in body weight and body mass index at baseline. We also observed a significant and negative correlation between change in HbA1c and HbA1c levels at baseline. The number of patients who showed the absence of urinary glucose was significantly increased after the sitagliptin treatment.

Effects of Sitagliptin May Depend on Clinical and Laboratory Data at the Baseline

“…We have previously reported that the 6-month sitagliptin treatment significantly reduced HbA1c, body weight in Japanese patients with type 2 diabetes [1]. We also found a negative correlation between changes in body weight and body mass index (BMI) at baseline, and also reported a negative correlation between changes in HbA1c and HbA1c levels at baseline [1].…”

“…We also found a negative correlation between changes in body weight and body mass index (BMI) at baseline, and also reported a negative correlation between changes in HbA1c and HbA1c levels at baseline [1].…”

“…We also found a negative correlation between changes in body weight and body mass index (BMI) at baseline, and also reported a negative correlation between changes in HbA1c and HbA1c levels at baseline [1].Kubota A et al reported that the 12 weeks-sitagliptin treatment significantly decreased HbA1c, serum total cholesterol and postprandial triglyceride levels, systolic blood pressure and diastolic blood pressure, and also increased serum creatinine [2]. However, we could not observe significant differences in systolic and diastolic blood pressure, and serum lipid levels, and estimated glomerular filtration rate (e-GFR) between before and after the sitagliptin treatment [1].…”

“…

We have previously reported that the 6-month sitagliptin treatment significantly reduced HbA1c, body weight in Japanese patients with type 2 diabetes [1]. We also found a negative correlation between changes in body weight and body mass index (BMI) at baseline, and also reported a negative correlation between changes in HbA1c and HbA1c levels at baseline [1].

Kubota A et al reported that the 12 weeks-sitagliptin treatment significantly decreased HbA1c, serum total cholesterol and postprandial triglyceride levels, systolic blood pressure and diastolic blood pressure, and also increased serum creatinine [2].

…”

A Croos Sectional Study in North Eastern Uttar Pradesh Population for the Estimation of Hdl, Triglycerides Levels in Recently Diagnosed Patients With Diabetes Mellitus Type 2 Taking Metformin Alone, Metformin With Add on Sitagliptin and Sitagliptin Alone

“…Yanai et al [3] had found a significant and negative correlation between change in body Another study performed by Seck et al [4] result was for the PP cohort, Relative to baseline, sitagliptin was associated with significant weight loss (p<0.05) (-1.6 kg) compared with weight gain (+0.7 kg) with glipizide. Study conducted by Yang et al [5] in 2012 revealed a small decrease from baseline body weight in the placebo group compared with no change in the sitagliptin group (between-group difference 0.5kg; p<0.01).…”